Previous close | 3.9500 |
Open | N/A |
Bid | 2.7500 |
Ask | 4.9000 |
Strike | 23.00 |
Expiry date | 2024-11-15 |
Day's range | 3.9500 - 3.9500 |
Contract range | N/A |
Volume | |
Open interest | 7 |
Myriad’s Prolaris Test is the only biomarker test to quantify the benefits of adding androgen deprivation therapy to radiation therapy1 SALT LAKE CITY, May 16, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, announced that JCO Precision Oncology has published a study showing a clinical cell-cycle risk (CCR) score can accurately predict the benefit of adding androgen deprivation therapy (ADT) to radiation therapy (RT) in men with
On May 15, 2024, Paul Diaz, President and Chief Executive Officer of Myriad Genetics Inc (NASDAQ:MYGN), executed a significant transaction by selling 227,844 shares of the company.
On May 13, 2024, Director Lee Newcomer sold 6,200 shares of Myriad Genetics Inc (NASDAQ:MYGN) as reported in a recent SEC Filing.